Literature DB >> 32199709

Diagnosis and Management of Pulmonary Hypertension in Patients With CKD.

Carl P Walther1, Vijay Nambi2, Nicola A Hanania3, Sankar D Navaneethan4.   

Abstract

Pulmonary hypertension (PH) is a highly prevalent and important condition in adults with chronic kidney disease (CKD). In this review, we summarize the definition of PH, discuss its pathophysiology and classifications, and describe diagnostic and management strategies in patients with CKD, including those with kidney failure treated by kidney replacement therapy. In the general population, PH is classified into 5 groups based on clinical presentation, pathology, hemodynamics, and management strategies. In this classification system, PH in CKD is placed in a diverse group with unclear or multifactorial mechanisms, although underlying cardiovascular disease may account for most cases. CKD may itself directly incite pulmonary circulatory dysfunction and remodeling through uremic toxins, inflammation, endothelial dysfunction, and altered vasoregulation. Despite several studies describing the higher prevalence of PH in CKD and kidney failure, along with an association with poor outcomes, high-quality evidence is not available for its diagnostic and management strategies in those with CKD. In CKD not requiring kidney replacement therapy, volume management along with treatment of underlying risk factors for PH are critical. In those receiving hemodialysis, options are limited and transition to peritoneal dialysis may be considered if recurrent hypotension precludes optimal volume control.
Copyright © 2020 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chronic kidney disease (CKD); death; dialysis; end-stage renal disease (ESRD); heart failure; kidney failure; mean pulmonary arterial pressure (PAPm); pulmonary arterial hypertension (PAH); pulmonary circulatory dysfunction; pulmonary hypertension (PH); review; vascular remodeling; volume management

Mesh:

Year:  2020        PMID: 32199709      PMCID: PMC7247937          DOI: 10.1053/j.ajkd.2019.12.005

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  80 in total

1.  Aortic Aging in ESRD: Structural, Hemodynamic, and Mortality Implications.

Authors:  Gérard M London; Michel E Safar; Bruno Pannier
Journal:  J Am Soc Nephrol       Date:  2015-10-16       Impact factor: 10.121

2.  Pulmonary Hypertension, Mortality, and Cardiovascular Disease in CKD and ESRD Patients: A Systematic Review and Meta-analysis.

Authors:  Mengyao Tang; Jonathan A Batty; Chiayu Lin; Xiaohong Fan; Kevin E Chan; Sahir Kalim
Journal:  Am J Kidney Dis       Date:  2018-02-09       Impact factor: 8.860

Review 3.  The Ebb and Flow of Echocardiographic Cardiac Function Parameters in Relationship to Hemodialysis Treatment in Patients with ESRD.

Authors:  Charalampos Loutradis; Pantelis A Sarafidis; Christodoulos E Papadopoulos; Aikaterini Papagianni; Carmine Zoccali
Journal:  J Am Soc Nephrol       Date:  2018-03-28       Impact factor: 10.121

4.  Prevalence, determinants and prognosis of pulmonary hypertension among hemodialysis patients.

Authors:  Rajiv Agarwal
Journal:  Nephrol Dial Transplant       Date:  2012-01-30       Impact factor: 5.992

Review 5.  Prostacyclin therapy for pulmonary arterial hypertension.

Authors:  Cheng-Huai Ruan; Richard A F Dixon; James T Willerson; Ke-He Ruan
Journal:  Tex Heart Inst J       Date:  2010

6.  An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension.

Authors:  B W Christman; C D McPherson; J H Newman; G A King; G R Bernard; B M Groves; J E Loyd
Journal:  N Engl J Med       Date:  1992-07-09       Impact factor: 91.245

7.  Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.

Authors:  A Giaid; M Yanagisawa; D Langleben; R P Michel; R Levy; H Shennib; S Kimura; T Masaki; W P Duguid; D J Stewart
Journal:  N Engl J Med       Date:  1993-06-17       Impact factor: 91.245

Review 8.  Endothelin receptor antagonists in pulmonary arterial hypertension.

Authors:  Richard N Channick; Olivier Sitbon; Robyn J Barst; Alessandra Manes; Lewis J Rubin
Journal:  J Am Coll Cardiol       Date:  2004-06-16       Impact factor: 24.094

9.  2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marc Humbert; Jean-Luc Vachiery; Simon Gibbs; Irene Lang; Adam Torbicki; Gérald Simonneau; Andrew Peacock; Anton Vonk Noordegraaf; Maurice Beghetti; Ardeschir Ghofrani; Miguel Angel Gomez Sanchez; Georg Hansmann; Walter Klepetko; Patrizio Lancellotti; Marco Matucci; Theresa McDonagh; Luc A Pierard; Pedro T Trindade; Maurizio Zompatori; Marius Hoeper
Journal:  Eur Heart J       Date:  2015-08-29       Impact factor: 29.983

Review 10.  Pulmonary hypertension in patients with chronic and end-stage kidney disease.

Authors:  Meghan E Sise; Andrew M Courtwright; Richard N Channick
Journal:  Kidney Int       Date:  2013-06-05       Impact factor: 10.612

View more
  3 in total

Review 1.  Short-Chain Fatty Acids in Chronic Kidney Disease: Focus on Inflammation and Oxidative Stress Regulation.

Authors:  Giorgia Magliocca; Pasquale Mone; Biagio Raffaele Di Iorio; August Heidland; Stefania Marzocco
Journal:  Int J Mol Sci       Date:  2022-05-11       Impact factor: 6.208

2.  Mortality, Kidney Failure, and Hospitalization Among Medicare Beneficiaries With CKD and Pulmonary Hypertension.

Authors:  Sankar D Navaneethan; Carl P Walther; L Parker Gregg; Shweta Bansal; Wolfgang C Winkelmayer; Vijay Nambi; Jingbo Niu
Journal:  Am J Kidney Dis       Date:  2021-04-24       Impact factor: 8.860

3.  Baseline Ratio of Soluble Fas/FasL Predicts Onset of Pulmonary Hypertension in Elder Patients Undergoing Maintenance Hemodialysis: A Prospective Cohort Study.

Authors:  Xiao-Han Ding; Xiaoliang Chai; Jin Zheng; Hong Chang; Wenxue Zheng; Shi-Zhu Bian; Ping Ye
Journal:  Front Physiol       Date:  2022-03-01       Impact factor: 4.566

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.